<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3659">
  <stage>Registered</stage>
  <submitdate>5/10/2012</submitdate>
  <approvaldate>5/10/2012</approvaldate>
  <nctid>NCT01703078</nctid>
  <trial_identification>
    <studytitle>Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis</studytitle>
    <scientifictitle>A Phase 1 Exploratory Trial Evaluating Safety and Tolerability of Topical Administration of Different Concentrations of an Ingenol Derivative Compared to Ingenol Mebutate Gel 0.05% Applied on Two Consecutive Days to Four Separate 25cm2 Treatment Areas on the Forearms of Subjects With Actinic Keratosis (Field Therapy)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LP0084-68</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Actinic Keratosis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ingenol once daily for two consecutive days

Active Comparator: Ingenol mebutate gel 0.05% - once daily for two consecutive days

Experimental: Ingenol derivative concentration 1 - once daily for two consecutive days

Experimental: Ingenol derivative concentration 2 - once daily for two consecutive days

Experimental: Ingenol derivative concentration 3 - once daily for two consecutive days


Treatment: drugs: Ingenol once daily for two consecutive days


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of a new ingenol derivative compared to ingenol mebutate gel applied topically once daily for two consecutive days to four separate treatment areas containing actinic keratosis on the forearm - Safety data to be collected via CRF entries of AEs/SAEs and photographs.</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate treatment responses on Actinic Keratosis of different concentrations of a new ingenol derivative gel compared to the ingenol mebutate gel as assessed by reduction in number of clinically visible selected AK lesions eight weeks after treatment - Assessed by Reflective Confocal Microscopy scoring of visible selected AK lesions</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must be male or female and at least 18 years of age.

          -  Female patients must be of non-childbearing potential or if of childbearing potential
             then negative serum and urine pregnancy test and using effective contraception

          -  Ability to provide informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  location of the selected treatment area within 5cm of an incompletely healed wound or
             within 5cm of a suspected basal cell carcinoma or squamous cell carcinoma

          -  undergone Cosmetic or therapeutic procedures within 2cm of the selected treatment area
             in the 2 weeks prior to Visit 2

          -  use of acid-containing therapeutic products within 2cm of the selected treatment area
             in the 2 weeks prior to Visit 2

          -  use of topical moisturisers/creams/lotions, artificial tanners or topical steroids
             within 2cm of the selected treatment areas in the 2 weeks prior to visit 2 Treatment
             with immunomodulators, or interferon/interferon inducers or systemic medications that
             suppress the immune system within 4 weeks of Visit 2

          -  Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 2 cm of the
             treatment area in the 8 weeks prior to visit 2

          -  use of systemic retinoids

          -  those who are currently participating in any other clinical trial

          -  females who are pregnant or are breastfeeding

          -  those known or suspected of not being able to comply with the requirements of the
             protocol or provide consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>41</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Dermatology Department - Woolloongabba</hospital>
    <postcode>4102 - Woolloongabba</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>LEO Pharma</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if the new ingenol derivative gels are as safe as
      and as well tolerated as ingenol mebutate gel when applied to AK lesions on the forearm for
      two consecutive days.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01703078</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hans P Soyer</name>
      <address>Dermatology Department, Brisbane Public Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>